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Key points:  
-The sphingosine-1-phosphate receptor 2 (S1PR2) is a bona fide tumor suppressor and 
transcriptionally regulated by the TGF-β/TGF-βR2/SMAD1 axis 
-The aberrant loss of SMAD1 expression is very common in DLBCL and provides a proliferative 
advantage to B-cells in vitro and in vivo  
 
Abbreviations: ChIP, chromatin immunoprecipitation; DLBCL, diffuse large B-cell lymphoma; 
FOXP1, forkhead box protein 1; SMAD, small mothers against decapentaplegic. 
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Abstract 
The sphingosine-1-phosphate receptor S1PR2 and its downstream signaling pathway is 
commonly silenced in diffuse large B-cell lymphoma (DLBCL), either by mutational 
inactivation or through negative regulation by the oncogenic transcription factor FOXP1. In this 
study, we have examined the upstream regulators of S1PR2 expression and have newly identified 
the TGF-β/TGF-βR2/SMAD1 axis as critically involved in S1PR2 transcriptional activation. 
Phosphorylated SMAD1 directly binds to regulatory elements in the S1PR2 locus as assessed by 
chromatin immunoprecipitation, and the CRISPR-mediated genomic editing of S1PR2, SMAD1 
or TGFBR2 in DLBCL cell lines renders cells unresponsive to TGF-β-induced apoptosis. 
DLBCL clones lacking any one of the three factors have a clear growth advantage in vitro, as 
well as in subcutaneous xenotransplantation models, and in a novel model of orthotopic growth 
of DLBCL cells in the spleens and bone marrow of MISTRG mice expressing various human 
cytokines. The loss of S1pr2 induces hyper-proliferation of the germinal center B-cell 
compartment of immunized mice and accelerates MYC-driven lymphomagenesis in spontaneous 
and serial transplantation models. The specific loss of Tgfbr2 in murine GC B-cells phenocopies 
the effects of S1pr2 loss on GC B-cell hyper-proliferation. Finally, we show that SMAD1 
expression is aberrantly downregulated in >85% of analyzed DLBCL patients. The combined 
results uncover an important novel tumor suppressive function of the TGF-β/TGF-
βR2/SMAD1/S1PR2 axis in DLBCL, and show that DLBCL cells have evolved to inactivate the 
pathway at the level of SMAD1 expression.  
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Introduction 
Diffuse large B-cell lymphoma (DLBCL) is the most commonly diagnosed lymphoma in adults. 
It arises de novo at nodal or extranodal sites or as a consequence of high-grade transformation of 
indolent lymphomas or leukemias such as follicular lymphoma, chronic lymphocytic leukemia 
(CLL) and marginal zone lymphoma (MZL).1,2,3 DLBCL represents a heterogeneous disease 
with molecular subtypes characterized by distinct gene expression profiles, specific sets of 
somatic mutations and differentially active intracellular signaling pathways.4 Three subtypes of 
DLBCL can be distinguished based on their gene-expression similarities to their presumed 
normal B-cell counterparts, with activated B-cell-like (ABC) DLBCL resembling the post-
germinal center plasmablast, germinal center B-cell-like (GCB) DLBCL deriving from GC B-
cells and primary mediastinal B-cell lymphoma (PMBL) arising from a rare subset of thymic B-
cells.5,6 One of the biomarkers that is used to discriminate between GCB and ABC DLBCL is the 
Forkhead Box Protein 1 (FOXP1), a transcription factor that is highly expressed in the ABC 
subtype and is associated with poor prognosis.7,8,9 FOXP1 predominantly functions as a repressor 
of protein-coding genes, several of which have documented tumor suppressive activities in B-
cells.10,11,12 We have recently identified the sphingosine 1-phosphate receptor 2 (S1PR2) as being 
negatively regulated by FOXP1 in ABC-DLBCL; its expression was inversely correlated with 
FOXP1 expression in a large cohort of DLBCL patients and was restored in DLBCL cell lines 
upon depletion of FOXP1.10 Thus, S1PR2 is aberrantly silenced due to FOXP1 overexpression in 
ABC-DLBCL; conversely, in GCB-DLBCL, the S1PR2 locus is subject to recurrent mutations 
that typically affect one of the two alleles.13 Therefore, the two main DLBCL subtypes have 
evolved distinct mechanisms of silencing S1PR2 expression, both of which result in inactivation 
of the downstream signaling pathway involving the small G-protein Gα13 (encoded by the 
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GNA13 gene), Rho and possibly the kinase AKT. The S1PR2/Gα13/AKT signaling axis has been 
implicated in the regulation of GC B-cell growth and dissemination.13 Several pieces of evidence 
indicate that S1PR2 serves as a bona fide tumor suppressor in DLBCL: (1) the forced, 
doxycycline-induced expression of S1PR2 in DLBCL xenografts strongly delays tumor 
outgrowth, (2) the loss of one S1PR2 allele is sufficient to predispose mice to c-MYC-driven 
lymphomagenesis, and (3) low S1PR2 expression, independently and in conjunction with high 
FOXP1 expression, represents a strong negative prognosticator of survival in patients with either 
subtype of DLBCL.10  
In this study, we have addressed the consequences of S1PR2 inactivation for normal and 
malignant B-cell fate and have investigated the mechanisms of S1PR2 regulation in normal B-
cells and in DLBCL. We show that the mutational inactivation of the S1PR2 locus by 
CRISPR/Cas9 provides a major proliferative advantage to DLBCL cell lines in vitro and in 
xenotransplantation models, and that the loss of one or both alleles of S1pr2 in murine GC B-
cells promotes hyper-proliferation of the GC compartment upon sheep red blood cell 
immunization. We further provide evidence in various cell culture, xenotransplantation and 
genetically manipulated mouse models of the tumor suppressive activity of a newly identified 
TGF-βR2/SMAD1/S1PR2 axis in DLBCL. 
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Methods 
Cell culture 
The panel of DLBCL cell lines used here includes four of GCB DLBCL subtype (SU-DHL-6, 
SU-DHL-16, SU-DHL5 and RC-K8) and two of ABC DLBCL subtype (OCI-Ly3, OCI-Ly10). 
Cell lines were subjected to human TGF-β-1 (referred to as TGF-β) (PreproTech) treatment at 
various concentrations and analyzed with respect to cell viability, apoptosis, S1PR2 expression 
by qRT-PCR, transcription factor binding to the S1PR2 promoter region by ChIP and protein 
expression by Western blot. Culture conditions, TGF-β treatment conditions, cell viability, 
proliferation and apoptosis assays, RNA extraction and qRT-PCR, siRNA transfections, CRISPR 
manipulations, ChIP-PCR and Western blotting techniques are all described in the supplemental 
methods.  
 
Animal experimentation 
NOD/SCID/IL2Rγ-/- (NSG) mice and CSFh;IL-3/GM-CSFh;hSIRPAtg;TPOh;Rag2-;γc- (MISTRG) 
mice14 were obtained from a local repository. Tgfbr2fl/fl mice (B6;129-Tgfbr2tm1Karl/J) were 
crossed with AID-Cre mice (B6;FVB-Tg(Aicda-cre)1Rcas/J, both from the Jackson 
Laboratories). S1pr2-/- mice15 were crossed with Emu-MYC mice expressing the c-MYC 
oncogene under the control of the Ig heavy chain enhancer (B6.Cg-Tg(IghMyc)22Bri/J, also 
from Jackson Laboratories)16 to obtain composite strains. For induction of germinal centers, 6-8 
week old mice were intraperitoneally immunized twice with a 10 day interval with 200µl of 10% 
sheep red blood cells (Innovative Research, Michigan, USA) and sacrificed 10 days after the last 
immunization. Spleens were processed and subjected to flow cytometric analysis. All flow 
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cytometry and staining procedures are described in the supplemental methods. MYCtg mice were 
examined and palpated two to three times weekly in order to detect signs of lymph node 
enlargement. Mice were sacrificed within 1 week of developing palpable tumors. Tumor cells 
pooled from the axillary and inguinal lymph nodes were cryopreserved in FCS with 10% DMSO. 
For serial transplantation studies, 1x106 cells were injected intravenously into wildtype BL6 mice 
in a volume of 100 µl. Mice were palpated every other day for signs of lymph node engraftment. 
For xenotransplantation studies, CRISPR clones or wildtype RC-K8 or SU-DHL-6 (10x106 cells 
in 200µl PBS) were injected subcutaneously into both flanks of 6-8 week old NSG mice, or 
intravenously in a volume of 100μl into 6-8 weeks old MISTRG mice for orthotopic growth. 
Once palpable tumors had formed in the subcutaneous model, the volume of the tumors was 
measured by calipers and calculated using the formula (A2xB)/2, where A is the shorter and B 
the longer tumor dimension. Once palpable, wildtype SU-DHL-6 tumors were treated every 72 
hours with 0.2μg human TGF-β (PreproTech) in a volume of 50μl reconstituted in 10mM Citric 
Acid and diluted in 0.1% BSA in 1x PBS. Control tumors were treated with 50μl 10mM Citric 
Acid/0.1% BSA diluted in 1x PBS. Intravenously injected mice were monitored three times a 
week for weight loss and other symptoms of disease. All animal studies were reviewed and 
approved by the Zürich Cantonal Veterinary Office (licenses 224/2014, 227/2015, 235/2015).  
 
Patient cohorts and SMAD1 immunohistochemistry 
Expression of SMAD1 was studied by immunohistochemistry on a phenotypically and 
genotypically well characterized collective of 76 patients uniformly treated with R-CHOP-14 
and prospectively followed-up in the Swiss Group for Clinical Cancer Research 38/07 clinical 
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trial (ClinicalTrials.gov NCT00544219)17 and on a retrospective collective of 184 primary 
DLBCL treated with rituximab-free regimens (mainly CHOP),18 of which 74 patients had 
complete (and compatible with the formers’) follow-up data. The primary polyclonal antibody 
(CellSignaling cs9743) was diluted 1:40 and incubated for 20 minutes in an automated 
immunostainer (Benchmark, Ventana/Roche) after heat-induced antigen retrieval with the CC1 
buffer for 40 minutes. 
 
Statistics 
All statistical analyses were performed using Graph Pad Prism software. Graphs represent means 
plus SEM of at least two independent experiments for cell culture work and medians for mouse 
experiments unless otherwise indicated in the figure legend. Statistical analysis was performed 
using two-tailed student’s t-test for in vitro assays, and using two-tailed Mann-Whitney test for 
in vivo studies as well as two-tailed Fisher’s exact test for correlations of mutational status and 
SMAD1 expression in the patient cohort.  
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Results 
Deletion of S1PR2 by CRISPR/Cas9 confers a strong growth advantage to DLBCL cell 
lines in vitro and in vivo. To confirm the putative tumor suppressive properties of S1PR2 in 
DLBCL, we used CRISPR to delete one or both alleles of the S1PR2 locus in a cell line that is 
particularly suitable for this purpose due to its low FOXP1 and corresponding high S1PR2 
expression (RC-K8; suppl. Figure 1A-B). Of the five S1PRs (S1PR1-5), only S1PR2 is 
expressed in DLBCL cells and controlled by FOXP1 expression (suppl. Figure 1C). Sequencing 
of the S1PR2 and the GNA13 genomic loci confirmed that both loci carry the wild type sequence 
in RC-K8 cells (suppl. Figure 1D). A CRISPR strategy (suppl. Figure 1E) was then used to 
delete the single S1PR2 exon in one or both alleles of the locus (suppl. Figure 1F). Three 
S1PR2+/- and two S1PR2-/- clones were grown from FACS-sorted single cells and compared with 
respect to their in vitro growth to three wildtype clones (S1PR2+/+) that had been subjected to the 
same electroporation and sorting procedures. Mono- and bi-allelically mutated clones exhibited a 
robust growth advantage over wildtype clones in vitro (Figure 1A); the same observation was 
made with S1PR2-/- clones generated using a second cell line (SU-DHL-6, Figure 1B). To 
address whether the growth advantage of S1PR2-/- clones was due to reduced apoptosis or due to 
enhanced proliferation, we flow cytometrically quantified the surface AnnexinV and nuclear 
Ki67 expression at various time points of the growth curve. Whereas apoptosis rates were similar 
across clones as determined by AnnexinV staining, S1PR2-/- clones showed significantly 
stronger Ki67 staining than S1PR2+/+ clones (suppl. Figure 1G,H).  S1PR2+/- and S1PR2-/- clones 
further also grew faster and formed larger tumors at the study end point compared to wildtype 
clones in a subcutaneous xenograft model of RC-K8 (Figure 1C-E). The NOD/SCID/IL2Rγ-/- 
(NSG) mice used for subcutaneous xenotransplantation do not support orthotopic growth of 
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DLBCL cell lines upon intravenous (i.v.) injection. We instead turned to an alternative 
immunodeficient mouse developed on the Rag2-/-IL2Rγ-/- background, termed MISTRG, which 
expresses the human cytokines M-CSF, IL-3, thrombopoietin, GM-CSF as well as SIRP1α, from 
the respective murine loci19 and is known to support improved (orthotopic) growth of various 
myeloid neoplasias and solid tumors.20,14,21 MISTRG mice supported the efficient engraftment of 
SU-DHL-6 cells, which grew in bone marrow and spleen; interestingly, S1PR2-mutant SU-DHL-
6 clones grew more rapidly in both bone marrow and spleen than wildtype clones, accounting for 
the higher frequencies of human cells identified by FACS in these organs (Figure 1F-H, suppl. 
Figure 1I). The combined data indicates that S1PR2 expression restricts tumor cell proliferation 
in a cell-autonomous manner, further supporting the concept that S1PR2 is a bona fide tumor 
suppressor in DLBCL. 
 
Loss of S1pr2 promotes hyper-proliferation of the germinal center B-cell compartment and 
increases lymphoma incidence in a spontaneous and a serial transplantation mouse model 
of DLBCL. DLBCL arises from germinal center and post-germinal center (GC) B-cells that 
reside in secondary lymphoid organs or in lymphoid tissues at extranodal sites. To address 
whether the expression of S1PR2 affects GC formation and GC B-cell proliferation, we 
immunized wildtype or S1pr2+/- mice with two doses of sheep red blood cells (SRBCs) and flow 
cytometrically quantified GC B cells, centrocytes and centroblasts in the spleen at the study end 
point. The frequencies and absolute numbers of centrocytes, centroblasts, and of all GC B-cells 
were increased in S1pr2+/- mice (Figure 2A-C, suppl. Figure 2A-D). The increase in GC B-cells 
could be attributed to an increase in the size of individual GCs, but not their multiplicity per 
spleen, as determined by Ki67 staining of spleen sections (Figure 2D-F, suppl. Figure 2E). As 
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previously observed in a small preliminary cohort,10 we confirmed that mice harboring a 
heterozygous S1pr2 mutation with an additional c-MYC transgene under the B-cell-specific 
immunoglobulin heavy chain enhancer showed accelerated lymphoma development compared to 
S1pr2-proficient mice harboring the c-MYC transgene (suppl. Figure 2F). When lymph node 
cells from S1pr2+/- or S1pr2+/+ c-MYC-transgenic mice were serially transplanted into wildtype 
mice we observed faster lymphoma development with transplanted S1pr2+/- cells relative to 
wildtype cells in recipient mice (Figure 2G-H, suppl. Figure 2G-H). These results suggest that 
S1PR2 controls GC B-cell proliferation and that the hyper-proliferation of GC B-cells due to loss 
of S1pr2 may represent an early, initiating event in lymphomagenesis. 
 
S1PR2 expression is regulated by TGF-β and SMAD signaling. We have previously shown 
that FOXP1 represses transcription at the S1PR2 locus by binding to two regulatory elements 
located 2.5 (referred to as S1PR2 H) and 5 kb (S1PR2 G) upstream of the transcription start 
site.10 However, little is known regarding activating transcription factors that regulate S1PR2 
expression. We therefore screened several cytokines known to affect normal B-cell biology for 
their effects on S1PR2 expression and found that the addition of TGF-β, but not of IL-3, IL-5 or 
IL-6, dose-dependently induced the expression of S1PR2 in a subset of cell lines analyzed 
(Figure 3A, suppl. Figure 3A,B), with SU-DHL-6 and Oci-Ly10 showing the strongest response, 
RC-K8 and Oci-Ly3 being completely unresponsive to TGF-β and SU-DHL-16 and SU-DHL-5 
showing a partial response. The effect of TGF-β was particularly strong when FOXP1 was 
simultaneously depleted by siRNAs (Figure 3B, suppl. Figure 3C); of note, TGF-β exposure had 
no effect on FOXP1 levels (suppl. Figure 3D), ruling out an indirect effect of TGF-β on S1PR2 
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expression via regulation of FOXP1. To examine which components of the TGF-β signaling 
pathway control the differential susceptibility of DLBCL cell lines to TGF-β treatment, we 
examined the expression of various SMAD transcription factors that were previously found to 
trans-activate target genes of the pathway in DLBCL.22 Whereas SMAD9 was not expressed in 
any of the cell lines and SMAD5 was expressed in both highly and moderately responsive cell 
lines, the expression of SMAD1 was selectively detected only in those cell lines that showed 
strong responses to TGF-β and strong SMAD1/5/9 phosphorylation (Figure 3C, suppl. Figure 
3E). We further examined the expression of the TGFβ receptor II (TGF-βR2) and found it to be 
universally expressed in all cell lines (Figure 3D, suppl. Figure 3F).  
To address whether the SMAD proteins bind to regulatory elements of the S1PR2 locus, we 
performed chromatin immunoprecipitation (ChIP) followed by qPCR specific for the regions 2.5 
(H) and 5 kb (G) upstream of the S1PR2 transcription start site. SMADs 1, 5 and 9 are all 
phosphorylated on serine residues by the active (ligand-bound) TGF-β receptor complex 
(consisting of type I and II receptor heterotetramer), which promotes the nuclear translocation of 
the complex and binding to chromatin. We therefore used a pSMAD1/5/9-specific antibody for 
ChIP, and found that pSMAD1/5/9 indeed precipitated with S1PR2 genomic DNA, especially 
when cells were exposed to TGF-β for 4 hours prior to ChIP; this effect was observed in the 
TGFβ-responsive cell lines SU-DHL-6 and Oci-Ly10, but not the resistant cell lines RC-K8 and 
Oci-Ly3 (Figure 3E). Speculating that FOXP1 and SMAD1 interact directly at the S1PR2 
promoter, we immunoprecipitated FOXP1 and checked for a possible co-precipitation of 
SMAD1; however, no evidence could be found to that end in a cell line that co-expresses both 
proteins (suppl. Figure 3G). 
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As S1PR2  signaling  has  previously been  shown  to  inhibit  AKT  phosphorylation  and  AKT-
driven  migration,13 we  speculated  that  TGF-β/SMAD1-induced S1PR2  expression  might  
impair  DLBCL  cell  survival  by  preventing  AKT-mediated  survival  signaling.  However, 
TGF-β treatment failed to affect AKT activation, as assessed by its auto-phosphorylation on 
serine 473, and also did not change overall AKT levels (suppl. Figure 3D) and thus does not 
appear to act through this pathway. The combined results indicate that TGF-β activates S1PR2 
expression, especially if the repressor FOXP1 is removed, and implicate the non-canonical TGF-
βR2/SMAD1/5/9 pathway, and in particular SMAD1, in the transcriptional activation of S1PR2. 
 
TGF-β induces S1PR2-dependent apoptosis in DLBCL cell lines in vitro and in vivo. We 
have shown in a previous study that forced S1PR2 expression kills DLBCL cell lines both in 
culture and in xenotransplantation models.10 To address whether TGF-β exposure and the 
concomitant endogenous S1PR2 upregulation is toxic to DLBCL cell lines, we treated cell lines 
showing differential responses to TGF-β (Figure 3A,C) with increasing doses of the cytokine. 
TGF-β exposure efficiently reduced cell viability and increased apoptosis dose-dependently; this 
effect was restricted to cell lines that upregulate S1PR2 upon TGF-β exposure and that are 
positive for SMAD1 (Figure 4A, suppl. Figure 4A,B). The effect was again particularly strong 
when FOXP1 was simultaneously depleted by siRNAs (Figure 4B). SU-DHL-6 clones that had 
been subjected to S1PR2 deletion failed to undergo apoptosis upon TGF-β exposure, suggesting 
a critical role of S1PR2 in TGF-β driven apoptosis (Figure 4C). The TGF-β-sensitive cell line 
SU-DHL-6 was further assessed with respect to its susceptibility to TGF-β treatment in a 
xenograft model. Regular doses of intratumorally administered TGF-β resulted in lower tumor 
volumes and increased S1PR2 expression at the study endpoint relative to the vehicle control 
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(Figure 4D-F, suppl. Figure 4C). The combined results indicate that TGF-β signaling is cytotoxic 
for DLBCL cells in vitro and in vivo, and suggest that the apoptosis-promoting activity of TGF-β 
requires S1PR2. 
 
Loss of TGF-β signaling in the GC compartment induces GC B-cell hyper-proliferation. To 
address in a genetic model whether the cell-intrinsic loss of TGF-β signaling in the GC B-cell 
compartment affects the GC reaction, we crossed Tgfbr2fl/fl mice with animals expressing Cre 
recombinase under the control of the GC-specific activation-induced cytidine deaminase 
promoter (AID-Cre). Mice lacking TGF-βR2 specifically in GC B-cells exhibited hyper-
proliferation of their GC B-cells, centroblasts and centrocytes upon one round of SRBC 
immunization (Figure 5A-C, suppl. Figure 5A-C) and thus phenocopied the loss of S1PR2 in this 
compartment. The overall increase in GC cells could be attributed to an increase in the size of 
individual GCs, but not of their multiplicity per spleen, as determined by Ki67 staining of spleen 
sections (Figure 5D,E, suppl. Figure 5D). Together, the results demonstrate a critical role of the 
TGF-βR2/SMAD1/S1PR2 axis in the physiological control of the GC reaction and show for the 
first time that GC B-cell intrinsic TGF-β signaling is required for GC confinement. 
 
TGF-β signaling via TGF-βR2 and SMAD1 controls the proliferation of DLBCL cells. To 
examine the contribution of the TGF-βR2/SMAD1 axis to cell death signaling in DLBCL in 
more detail, we inactivated SMAD1 and TGFβR2 in the SU-DHL-6 cell line by editing their first 
exons (suppl. Figure 6A,B) and exposing several clones each to TGF-β. The loss of SMAD1 and 
TGFβR2 rendered clones resistant to TGF-β-induced apoptosis and reduced their S1PR2 
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expression (Figure 6A,B). The contribution of SMAD1 to TGF-β-induced apoptosis could 
further be confirmed by a SMAD1-specific siRNA (Figure 6C, suppl. Figure 6C-D). Clones 
lacking either SMAD1 or TGFβR2 grew faster than wild type clones and thus phenocopied the 
effect of S1PR2 inactivation in terms of their growth advantage in vitro (Figure 6D). Clones 
lacking SMAD1, but not those lacking TGFβR2, also grew faster and formed larger tumors when 
growing as subcutaneous xenografts on the flanks of NSG mice (Figure 6E, suppl. Figure 6E) 
and both SMAD1 and TGFβR2 knockout clones engrafted more readily in the spleen and the 
bone marrow when injected i.v. into MISTRG mice (Figure 6F). Furthermore, analysis of 
SMAD1 expression in a panel of 11 DLBCL cell lines confirmed its expression only in two cell 
lines (suppl. Figure 6F). Correlation analysis in the cell line panel confirmed the negative 
correlation between FOXP1 and S1PR2 expression and showed a trend towards a positive 
correlation between SMAD1 and TGF-βR2 versus S1PR2 expression (suppl. Figure 6G).   The 
combined results indicate that TGF-β signals via TGF-βR2 and SMAD1 to control S1PR2 
expression and DLBCL survival in vitro and restrict tumor growth in vivo.  
 
The expression of SMAD1 is aberrantly downregulated in DLBCL patients. To test the 
clinical relevance of our observations in two Swiss patient cohorts, we studied the expression of 
SMAD1 by immunohistochemistry performed on tissue microarrays. 75 patient samples of a 
uniformly R-CHOP treated collective and 184 patients of a CHOP-treated collective were 
evaluable. Only 7 of the 75 (9.3%) and 29 of the 184 patients (15.7%), respectively, were found 
to express SMAD1 in 10 to 90% of tumor cells (Figure 6G); in all other (negative) cases, internal 
positive controls (vessels) stained as expected, but the lymphoma cells did not show SMAD1 
positivity. In contrast, SMAD1 staining of normal tonsil samples showed uniformly positive 
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SMAD1 expression in centrocytes, but not centroblasts (suppl. Figure 6H). In both cohorts, the 
fraction of SMAD1-positive cases was equally low in patients with GCB (15%) and non-GCB 
(ABC; 13%) DLBCL subtype. The results indicate that SMAD1 is selectively downregulated in 
DLBCL, irrespective of the subtype. Further analyses of SMAD1 expression in relation to 
clinical characteristic of the patients, and the mutational profiles of the tumors as assessed by 
targeted high-throughput sequencing of all exons or hotspots of 68 frequently mutated genes, 
revealed that SMAD1 was more commonly expressed in CD79b mutant cases (2/4 vs. 2/70, 
p=0.041), in female patients (in the respective collectives: 6/34 vs. 1/41, p=0.030 and 14/60 vs. 
16/124, p=0.043) and, not statistically significant, in MYD88 mutant cases (p=0.066). We also 
examined whether aberrant silencing of SMAD1 was more common in patients with wild type 
GNA13 than in patients with mutations in this important downstream mediator of S1PR2 
signaling. 13 of 75 analyzed patients (17.3%) exhibited GNA13 mutations. Among GNA13-wild 
type tumors, 7 of 62 were positive for SMAD1 (11.2%), whereas 0 of 13 GNA13-mutant tumors 
were SMAD1-positive (0%). The difference was not statistically significant (p=0.25). In 
conclusion, SMAD1 expression is aberrantly silenced in a large majority of GCB and non-GCB 
DLBCL cases, which does not appear to be (inversely) correlated with inactivating mutations in 
the S1PR2/Gα13 signaling pathway. 
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Discussion 
A growing body of evidence implicates S1PR2 as a novel, and uniformly important, tumor 
suppressor that is mutationally or transcriptionally inactivated in both major subtypes of 
DLBCL. In the GC B-cell subtype, the S1PR2 locus, as well as genes encoding downstream 
components of the signaling pathway such as GNA13, are subject to recurrent mutational 
inactivation.13 In the ABC subtype arising from post-germinal center plasmablasts, S1PR2 is 
repressed due to high FOXP1 expression (Figure 7), with FOXP1 acting as a direct negative 
regulator of S1PR2 expression by binding to two elements in the promoter region of the S1PR2 
gene.10 In this study, we uncover a third and very common mechanism of S1PR2 downregulation 
that affects >85% of our patient cohort and the majority of examined DLBCL cell lines and 
involves the aberrant silencing of SMAD1. In SMAD1-expressing DLBCL cells, SMAD1 
functions alongside other components of the non-canonical SMAD1/5/9 signaling complex in 
relaying signals from the type II TGF-β receptor upon binding of its ligand TGF-β (Figure 7). 
Whereas the receptor itself is universally expressed on all examined cell lines in our panel and 
appears to not be the limiting factor restricting signaling activity of the pathway, SMAD1 
expression is absent in the majority of our cell lines (and of our cohorts), possibly reflecting its 
transcriptional silencing by DNA methylation. The knock down of SMAD1 by RNAi, or the 
CRISPR-mediated editing and inactivation of the SMAD1 gene in SMAD1-positive DLBCL 
cells, both inhibit TGF-β−dependent S1PR2 expression, indicating that SMAD1-negative cases 
of DLBCL likely are unresponsive to the pro-apoptotic activities of this cytokine in vivo. We 
indeed found in various xenotransplantation settings and under cell culture conditions, that 
SMAD1 and TGF-βR2 are not only required for S1PR2 expression, but also for the induction of 
apoptosis by TGF-β, which in turn was dependent on S1PR2 as judged by the pro-apoptotic 
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response of S1PR2-proficient but not –deficient DLBCL clones to TGF-β. DLBCL clones 
lacking SMAD1, or TGF-βR2, or S1PR2 expression all have a growth advantage over wildtype 
clones in vitro and in vivo. This effect was particularly evident in a novel model of orthotopic 
DLBCL growth that allows for efficient engraftment of various cell lines, including the SU-
DHL-6 used here, in the spleen and bone marrow of MISTRG mice. The new model overcomes 
the current limitations in DLBCL research by providing a versatile, practical, fast and readily 
available model for in vivo work that, especially in combination with CRISPR manipulation of 
the transplanted cell lines, lends itself to multiple applications, including drug testing.  
The observation that TGF-β activates non-canonical SMAD1/5/9 signaling via TGF-βR2 in 
normal B-cells and in various other cell types is not new,23,24,25,26,27 and some evidence is 
available for the concept that this process is impaired in malignant B-cells. For example, in 
Burkitt lymphoma and in Epstein–Barr virus-transformed B-lymphoblastoid cell lines, reduced 
TGF-βR2 expression renders cells partially resistant to TGF-β.28 Point mutations in TGF-βR2 
were found to inhibit its tumor suppressive activities in cutaneous T-cell lymphoma.29 
Furthermore, TGF-βR2 expression has been proposed as a positive prognostic factor in DLBCL 
patients,30 an observation that fits very well with our model. Large scale screening and drug 
testing efforts have identified the TGF-β signaling pathway as a promising target in DLBCL that 
may be exploited for chemo-sensitization purposes.31,32,33 Our results thus provide a mechanistic 
link between two previously known or suspected tumor suppressive pathways frequently 
inactivated in DLBCL- one involving aberrant inactivation of S1PR2 signaling and its pro-
apoptotic activities, and the other involving the TGF-β signaling pathway. SMAD1 links the two 
pathways by directly binding to the S1PR2 promoter once it is phosphorylated by ligand-bound 
TGF-βR2 and has translocated to the nucleus. 
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Mechanistic evidence from animal models, presented here and in two previous studies,34,35 
suggests that S1PR2 inactivation represents an early event in DLBCL initiation. The loss of only 
one functional allele of S1pr2 was sufficient to predispose mice to hyper-proliferation of the GC 
compartment upon immunization, a phenotype that was recapitulated by the loss of one or both 
copies of Tgfbr2. Both centrocytes and centroblasts were more numerous in the absence of S1pr2 
or Tgfbr2 and their over-representation in splenocyte preparations could be linked to larger rather 
than more numerous GCs. The fact that there is no reliable S1PR2 antibody available did not 
allow us to confirm the decreased S1PR2 expression in heterozygous knockout mice, 
nevertheless the clear phenotype of these mice strongly suggests that the mice have a lower 
receptor expression upon loss of one copy of S1pr2. The fact that S1PR2 plays an important role 
in GC confinement has been shown previously35 and has been linked to a gradient of S1P within 
the GC that prevents GC cells from prematurely exiting the compartment. Our data suggest that 
an additional layer of regulation exists that involves TGF-β acting further upstream within GC 
B-cells to control S1PR2 expression. This model is supported by the observations that tonsillar 
centrocytes, but not centroblasts express high levels of SMAD1, and that the S1PR2 repressor 
FOXP1 is downregulated in the GC B-cell compartment.10  
Several lines of evidence suggest that S1PR2 acts cell-intrinsically in tumor B-cells, rather than 
in tumor-infiltrating non-malignant cells to promote cell death (for example in response to TGF-
β) and/or to limit the proliferative capacities of normal and malignant B-cells. This model is 
supported by the hyper-proliferation of S1PR2-deficient DLBCL cells in vitro and in vivo, by the 
fact that MYC-expressing murine lymphoma cells, injected i.v. into wildtype recipient mice, 
form larger tumors in lymph nodes and spleen if they lack one copy of S1pr2, and by our 
previous observation that forced expression of S1PR2 reduces tumor size in established 
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lymphomas.10 Patients with low S1PR2 expression have a significantly worse prognosis than 
patients with high S1PR2 expression, and the benefits of high S1PR2 expression are especially 
obvious in combination with low FOXP1 expression.10 In summary, we show here for the first 
time that two major tumor suppressive pathways in DLBCL intersect at the level of the 
transcription factor SMAD1, which mediates pro-apoptotic TGF-β signaling by binding directly 
to the S1PR2 promoter and thereby activating S1PR2 expression, a process that is particularly 
efficient in the absence of the repressor FOXP1 (Figure 7). In accordance with its critical role in 
TGF-β-driven apoptosis, SMAD1 expression is aberrantly low or absent in a large majority of 
DLBCL patients. The combined results reveal an important novel tumor suppressive function of 
the TGF-β/TGF-βR2/SMAD1/S1PR2 axis in DLBCL, and demonstrate for the first time that 
DLBCL cells have evolved to inactivate this cell death-promoting pathway at the level of 
SMAD1 expression.  
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Figure Legends 
 
Figure 1. Genomic editing of the S1PR2 locus provides a growth advantage to DLBCL cell 
lines in vitro and in vivo. (A,B) The DLBCL cell lines RC-K8 (A) and SU-DHL-6 (B) were 
subjected to S1PR2 inactivation using CRISPR/Cas9 editing. Absolute cell counts of two to three 
independent clones derived from FACS-sorted single cells of the indicated genotypes were 
compared under standard cell culture conditions over ten days without medium change. Pooled 
results from two out of a total of four independent experiments (A) and of four independent 
experiments (B) are shown. p-values were calculated using the student t- test on the average 
value for each genotype pooling S1PR2+/- and S1PR2-/- clones. (C-E) Ten million cells each of 
five S1PR2+/+ clones (red), four S1PR2+/- clones (blue) and two S1PR2-/- clones (all in the RC-K8 
cell line; black) were injected subcutaneously into the flanks of NSG mice. Tumors were 
excised, representative macroscopic images were taken (C), and tumor weights (D) and volumes 
(E) were determined at the study endpoint 40 days post injection. Every dot represents one tumor 
and plots show pooled data from two independent experiments. (F-H) Ten million cells per 
mouse of two to three replicates each of three independent S1PR2+/+ clones (red) and three 
S1PR2-/- clones (all in the SU-DHL-6 cell line; black) were injected intravenously into MISTRG 
mice. Mice were sacrificed 35 days after tumor cell injection, their spleens were weighed (F) and 
the frequencies of hCD45+ cells in the spleen (G) and the bone marrow (H) was determined by 
flow cytometry. Every dot represents one mouse and graphs represent pooled data from two 
independent experiments. In D-H, horizontal lines indicate medians and p-values were calculated 
using the Mann-Whitney test. *p<0.05; **p<0.01; ***p<0.001. 
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Figure 2. The mono-allelic loss of S1pr2 promotes hyper-proliferation of the germinal 
center B-cell compartment and increases the lymphoma burden in a spontaneous and a 
serial transplantation model of MYC-driven lymphomagenesis. (A-F) S1pr2+/+ and S1pr2+/- 
mice on the BL/6 background were immunized twice intraperitoneally with 200 μl 10% sheep 
red blood cells (SRBCs), with a ten day interval between the two immunizations. Mice were 
sacrificed ten days after the last immunization and GC B-cells were flow cytometrically 
identified as CD95hi CD38lo in the CD19+ B-cell compartment (A-C). GC B-cell frequencies in 
% of all CD19+ B-cells as well as absolute numbers per spleen are shown in A and B, alongside 
representative FACS plots in C. Non-immunized littermates are shown as control. (D-F) The GC 
area (arbitrary units) of immunized mice was determined by quantifying three Ki-67-stained 
spleen sections per mouse using ImageJ (D). Representative pictures of spleens of immunized 
S1pr2+/+ and S1pr2+/- mice are shown in E and F. Size bar represents 1000μm; arrows point to 
GCs. Every dot in A, B and D represents one mouse and data from five pooled experiments are 
shown. (G,H) One million lymph node cells per mouse, harvested from three S1pr2+/+ and three 
S1pr2+/- MYCtg donor mice of the cohorts shown in supplemental Figure 2F were injected 
intravenously into wildtype BL/6 recipients. Mice were palpated every other day for enlarged 
lymph nodes and sacrificed after 20 days, i.e. when the first mice showed disease symptoms. 
Spleen weights (G) and lymph node weights (H) were determined. Lymph node weights 
represent the average of two inguinal and two axillary lymph nodes. Control mice were not 
injected with tumor cells. In A, B, D, G and H, horizontal lines indicate medians and p-values 
were calculated using the Mann-Whitney test. *p<0.05; **p<0.01. 
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Figure 3. S1PR2 expression is regulated by the TGF-β/SMAD signaling pathway. (A) 
S1PR2 expression after 24h of treatment with the indicated increasing doses of TGF-β, as 
assessed in the SU-DHL-6, Oci-Ly10, RC-K8 and Oci-Ly3 DLBCL cell lines by qRT-PCR. (B) 
The DLBCL cell line SU-DHL-6 was treated with FOXP1 targeting siRNA for 48h and 
subjected to treatment with 2 ng/ml TGF-β for an additional 24h. Data in A and B are pooled 
from three or more independent experiments. Graphs show mean +SEM; p-values were 
calculated using the student t-test. (C) The indicated DLBCL cell lines were treated with 2 ng/ml 
TGF-β for 1h and subjected to immunoblotting with antibodies against the indicated SMAD 
proteins, p-SMAD1/5/9 and tubulin. Representative immunoblots of at least two independent 
experiments are shown. (D) TGF-βR2 surface expression of the indicated DLBCL cell lines, as 
assessed by flow cytometry. The plots are representative for two independent experiments. (E) 
pSMAD1/5/9 ChIP of cells treated or not with 5 ng/ml TGF-β for 4h; an unspecific rbIgG 
antibody was used as control. Eluted DNA was subjected to PCR using primers amplifying two 
regions 2.5 and 5 kb upstream of the S1PR2 TSS. MyoD was amplified as negative control; 
CDKN1A and ID1 were used as positive controls for canonical TGF-β and BMP signaling. 
Graphs represent the fold change of the yield relative to 1% input of the pSMAD1/5/9 sample 
versus rbIgG; means +SD of two independent experiments are shown. *p<0.05; **p<0.01; 
***p<0.001; ****p<0.0001. 
 
Figure 4. TGF-β induces S1PR2-dependent apoptosis in DLBCL cell lines in vitro and in 
vivo. (A) Cell viability and apoptosis, as determined by Cell Titer Blue assay and annexin V 
staining, of the indicated cell lines after 24h of exposure to increasing concentrations of TGF-β; 
values are normalized to the untreated control sample. (B) The DLBCL cell line SU-DHL-6 was 
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treated with FOXP1 targeting siRNA for 48h, subjected to 2 ng/ml TGF-β for additional 24h, 
and analyzed as described in A. Data in A and B are pooled from three or more independent 
experiments. Graphs show means +SEM; p-values were calculated using the student t-test. (C) 
Three S1PR2+/+, one S1PR2+/- and three S1PR2-/- clones generated in the SU-DHL-6 cell line 
were treated with 2 ng/ml TGF-β and analyzed for apoptosis by annexinV staining. Bars 
represent pooled data for each genotype relative to the untreated control of each clone. Each 
clone was analyzed three to six times. Graphs represent means +SEM; p-values were calculated 
using the student t-test. (D-F) Ten million SU-DHL-6 cells were injected subcutaneously into 
both flanks of NSG mice. One tumor per mouse was injected intratumorally with TGF-β at the 
depicted intervals (D), and the other received vehicle only. Tumor volumes were measured after 
excision (E) and RNA was extracted and qRT-PCR for S1PR2 was performed on excised tumor 
tissue (F). In F, each dot represents one tumor and results are pooled from two independent 
experiments. S1PR2 expression analysis was only performed in one of the two studies with n=10 
per group. Two control and one TGF-β-treated tumor had to be excluded due to insufficient RNA 
quality. TGF-β-treated and control tumors are compared for each mouse. p-values were 
calculated using the Mann-Whitney test. *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
 
Figure 5. Loss of TGF-β signaling in the GC compartment induces GC B-cell hyper-
proliferation. (A-E) Tgfbr2fl/fl mice were crossed with AID-Cre mice; Tgfbr2wt/wt, Tgfbr2fl/wt and 
Tgfbr2fl/fl x AID-Cre mice were immunized intravenously with 200 μl 10% SRBCs, sacrificed 
ten days after immunization and GC cells were analyzed by flow cytometry as described in 
Figure 2. GC B-cell frequencies in % of all CD19+ B-cells as well as absolute numbers per 
spleen are shown in A and B, alongside representative FACS plots in C. Non-immunized 
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littermates are shown as control. (D,E) The GC area (arbitrary units) of immunized mice was 
determined by quantifying three Ki-67-stained spleen sections per mouse using ImageJ (D). 
Representative pictures of spleens of immunized mice of the indicated genotypes are shown in E. 
Size bar represents 1000μm; arrows point to GCs. Every dot in A, B and D represents one mouse 
and data from three pooled experiments are shown. Graphs show Medians. *p<0.05; **p<0.01. 
 
Figure 6. TGF-β signaling via TGF-βR2 and SMAD1 activates S1PR2 expression and 
induces apoptosis of DLBCL cells and SMAD1 expression is downregulated in DLBCL 
patients. (A) Three SMAD1+/+ and two SMAD1-/- as well as three TGFβR2+/+ and three TGFβR2-
/- clones (all generated in the SU-DHL-6 cell line) were treated with 2 ng/ml TGFβ for 24 h and 
analyzed for apoptosis with annexin V staining. Bars represent pooled data for each genotype 
relative to the untreated control of each clone. (B) The same clones as in A were subjected to 
RNA extraction and S1PR2-specific qRT-PCR. Each clone in A and B was analyzed twice, 
graphs represent means +SEM; p-values were calculated using the student t-test. (C) The 
DLBCL cell line SU-DHL-6 was treated with SMAD1-targeting siRNA for 48h and subjected to 
2 ng/ml TGFβ for additional 24h. Cells were analyzed for apoptosis by annexinV staining. 
Graphs show pooled results from six independent experiments. Means +SEM are represented. p-
values were calculated using the student t-test. (D) Absolute cell counts of two to three 
independent clones derived from FACS-sorted single cells of the indicated genotypes were 
compared under standard cell culture conditions over ten days without medium change. Two 
experimental replicates are shown. p-values were calculated using the student t- test on the 
average value for each genotype. (E) Ten million cells each of three SMAD1+/+ clones (grey), and 
two SMAD1-/- clones (red, in SU-DHL-6) were injected subcutaneously into the flanks of NSG 
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mice. Tumors were excised and tumor weights and tumor volumes were determined at the study 
endpoint 24 days after injection. Every dot represents one tumor and plots show pooled data 
from two independent experiments. (F) Ten million cells of six SMAD1/TGFβR2+/+ clones (grey) 
and two SMAD1-/- (red) or three TGFβR2-/- (blue, all in SU-DHL-6) clones were injected 
intravenously into MISTRG mice. Mice were sacrificed 35 days post injection, their spleens 
were weighed and the frequencies of hCD45+ cells in the spleens and bone marrow was 
determined by flow cytometry. Every dot represents one mouse and graphs represent data from 
three experiments. Horizontal lines in E and F indicate medians and p-values were calculated 
using the Mann-Whitney test.  (G) Negative (left) and positive (right) SMAD1 
immunohistochemical staining of DLBCL patient samples. Size bar represents 20μm *p<0.05; 
**p<0.01; ***p<0.001; ****p<0.0001. 
 
Figure 7. Schematic summarizing the tumor suppressive properties of the TGF-
β/SMAD1/S1PR2 axis in DLBCL. Under physiological conditions, centrocytes and centroblasts 
express large amounts of S1PR2, which promotes GC confinement due to a gradient of S1P that 
increases in concentration towards the borders of the GC and leads to apoptosis in GC cells that 
attempt to exit the GC. In DLBCL, S1PR2 is either mutated (in the GCB subtype) or 
transcriptionally downregulated by FOXP1 (in the ABC subtype). Loss of S1PR2 thus is an early 
initiating event in both major subtypes of DLBCL. The expression of S1PR2 is further regulated 
by TGF-β, which binds to its receptor TGF-βR2 and activates SMAD1 phosphorylation and 
nuclear translocation. p-SMAD1 binds directly to regulatory elements in the S1PR2 promoter 
and activates S1PR2 expression; most cases of DLBCL exhibit aberrantly low or absent 
expression of SMAD1. 
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